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Abstract
Infusion of human third-party mesenchymal stromal cells (MSCs) appears to be a promising therapy for acute graft-versus-
host disease (aGvHD). To date, little is known about how MSCs interact with the body’s innate immune system after clinical
infusion. This study shows, that exposure of MSCs to blood type ABO-matched human blood activates the complement
system, which triggers complement-mediated lymphoid and myeloid effector cell activation in blood. We found deposition
of complement component C3-derived fragments iC3b and C3dg on MSCs and fluid-phase generation of the chemotactic
anaphylatoxins C3a and C5a. MSCs bound low amounts of immunoglobulins and lacked expression of complement
regulatory proteins MCP (CD46) and DAF (CD55), but were protected from complement lysis via expression of protectin
(CD59). Cell-surface-opsonization and anaphylatoxin-formation triggered complement receptor 3 (CD11b/CD18)-mediated
effector cell activation in blood. The complement-activating properties of individual MSCs were furthermore correlated with
their potency to inhibit PBMC-proliferation in vitro, and both effector cell activation and the immunosuppressive effect
could be blocked either by using complement inhibitor Compstatin or by depletion of CD14/CD11b-high myeloid effector
cells from mixed lymphocyte reactions. Our study demonstrates for the first time a major role of the complement system in
governing the immunomodulatory activity of MSCs and elucidates how complement activation mediates the interaction
with other immune cells.
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Introduction
Based on their immunomodulatory properties, mesenchymal stem
or stromal cells (MSCs) are under investigation as treatment for acute
graft-versus-host disease (aGvHD) and other types of hematopoietic
stem cell transplantation-related disorders [1,2,3]. Their production
of trophic factors also makes MSCs valuable candidates for many
types of tissue repair applications [4,5]. The unique potential of
MSCs to provide therapeutic options for thus-far untreatable human
diseases is overshadowed by their difficult handling [6]. It is not clear
yet how to assess the therapeutic potency of these cells before clinical
administration to individual donors. Thus, it becomes clear that a
more thorough mechanistic characterization of the most effective cell
therapy product is urgently needed [5].
The exact mechanism by which MSCs elicit the broad
immunomodulatory effect in vivo is at present unclear [5]. Is has
been observed that intravenous administration of MSCs promotes
a beneficial effect on damaged tissues by inhibiting apoptosis,
stimulating cell regeneration, and increasing angiogenesis [5,7]. It
appears that MSCs reprogram recipient immune cells [8,9,10], for
generating a complex immunosuppressive milieu consisting of a
multitude of factors with complementary functions [6]. MSCs
thereby synergize with the host’s immune system to potently
suppress acute immune responses, in a fashion similar to that
described for the process of tumor immune modulation [11]. The
complement system serves as an important signalling system for
modifying immune responses [12], e.g., in modulating the anti-
tumor immune response [13,14]. Complement integrates the
interaction between innate and adaptive immunity, it may be a key
mediator of the broad immune modulation elicited by the
therapeutic application of these cells, and it may possibly
contribute to the generation of the immunosuppressive environ-
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anaphylatoxins C3a and C5a participate in activation and
recruitment of MSCs to sites of tissue damage and repair [15].
MSCs, like many other cell therapy treatments, can be applied
via intravenous infusion into the blood circulation. These
treatments are generally characterized by a high rate of cell loss
[16]. This may be due to the instant blood-mediated inflammatory
reaction (IBMIR) [17], which is characterized by a rapid
destruction of the infused cells due to complement-, coagulation-
and platelet activation. Complement rapidly reacts against foreign
pathogens and cooperates with innate immune cells to clear these
alien structures [18]. The central step in complement activation,
regardless of the triggering event, is the proteolytic cleavage of
complement component C3 (187 kDa) into C3b (177 kDa) and
C3a (9 kDa) [19]. This cleavage reaction leads to disruption of the
highly reactive internal thioester group and allows the subsequent
covalent attachment of C3b to the triggering surface. C3b can
then undergo a series of proteolytic cleavages to produce the
surface-bound fragments iC3b and C3dg. These cell-bound
fragments are ligands for immune cells bearing complement
receptor type 1 (CR1; CD35), CR2 (CD21), CR3 (CD11b/CD18),
and CR4 (CD11c/CD18); with CR3 being most prominent on
monocytes, macrophages and NK-cells. Once complement
activation occurs, the soluble anaphylatoxins C3a and C5a are
released, which attract and activate leukocytes [12]. C5a-receptor
signalling leads to up-regulation of CD11b on myeloid cells, to
promote the interaction with its ligand iC3b [20]; this reaction can
be blocked with a small cyclic C5a-receptor antagonist [21], or by
inhibiting cleavage of C3 with the cyclic peptide Compstatin [22].
Recently, complement activation was identified to be a major
requisite for tumor cell-induced myeloid suppressor cell-generation
in vivo, next to other soluble mediators such as PGE2, VEGF, IL-6
and IL-1b [13,14]; all well known to be engaged in MSC-
mediated immune modulation and evasion [6].
The aim of the present study was to characterize the interaction
of culture-expanded human MSCs with the human complement
system, and to analyze the resulting effector cell responses in
human blood, in order to optimize this immunomodulatory
treatment, and to find ways for improving the therapeutical
efficiency of this novel treatment.
Materials and Methods
Ethics statement, MSC recipients and clinical grade MSCs
Human MSCs were obtained from bone marrow aspirates
following approval by the ethics committee and review board at
Karolinska University Hospital Huddinge, Sweden. The expan-
sion and characterization of MSCs was performed according to
the guidelines of the MSC consortium of the European Blood and
Marrow Transplantation Group (EBMT), and was approved by
the Swedish Medical Products Agency, as previously described in
detail [2]. MSCs were isolated and characterized as described
previously [1,23]. Donors and patients, or their legal guardians,
gave written informed consent [1], and the study was approved by
the Regional Ethics Review Board. All patients have previously
been reported [1,3]. Forty-two MSC recipients who underwent
hematopoietic stem cell transplantation (HSCT) at the Karolinska
University Hospital, Huddinge, Sweden and received treatment
with MSC, between the years of 2003 and 2010 were included in
the analysis. Patients received myeloablative (n=26) or reduced
intensity conditioning (n=16) and GvHD prophylaxis, according
to previously published procedures [1]. The indications for MSC
administration were failure of standard treatment approaches for
acute GvHD refractory to standard therapy in 28 patients, and
tissue injury after HSCT (hemorrhagic cystitis and pneumomedi-
astinum) in 14 patients. Patients received MSC-infusions from 3
rd
party unrelated donors (n=50), from haploidentical related
donors (n=11) and from HLA identical siblings (n=3). Patients
received MSCs from passage 1 to 4 (P1-4) in doses of
approximately 1.0 to 3.0610
6 cells/kg. All MSC donors (n=33)
were considered healthy after assessment of medical history,
physical examination, and serological screening for HIV and
hepatitis viruses. For fast availability, most of the applied cells were
stored in liquid nitrogen and freshly thawed for IV-infusion. The
MSC suspensions were culture-negative for bacteria and fungi,
and polymerase chain reaction negative for Mycoplasma pneu-
moniae [2].
Isolation and culture of cells for experiments
To isolate MSCs, bone marrow mononuclear cells were
separated over a gradient of Redigrad (GE Health Care, Uppsala,
Sweden), washed and resuspended in DMEM low-glucose
medium (DMEM-LG; Gibco, Paisley, UK), supplemented with
100 IU/ml penicillin, 0.1 mg/ml streptomycin, and 10% fetal calf
serum (FCS; Gibco), and plated at 1.6610
5 cells/cm
2. When the
cultures neared confluence (.80%), the cells were detached by
treatment with trypsin and EDTA (Invitrogen, Grand Island, NY)
and replated/passaged at a density of 4.000 cells/cm
2. HUVECs
(Promocell, Heidelberg, Germany) were grown in endothelial cell
growth medium (Promocell), supplemented with 100 IU/ml
penicillin and 0.1 mg/ml streptomycin and replated at 10.000
cells/cm
2. Cells for experiments were detached with trypsin,
viability was assessed by trypan blue exclusion (generally .95%),
and cell suspensions were adjusted to 1-2610
6 cells/ml.
Blood and serum preparations
Fresh non-anticoagulated human blood was obtained from
healthy volunteers who had given informed consent in accordance
with the Helsinki Protocol and received no medication for at least
10 days. Complement-active normal human AB serum (NHS) was
processed within 1 h of blood collection and stored at -70uC, to
maintain the complement activity. In all experiments that made
use of human serum, the final concentration of NHS or NHS/
EDTA was 50% (v/v). Whole blood flow cytometry was
performed with blood that had been anticoagulated by using
0.05 mg/ml lepirudin to (Refludan; Hoechst, Frankfurt am Main,
Germany), a specific thrombin inhibitor that maintains the
complement function in blood. To block complement function,
blood or NHS was treated with cyclic Compstatin Ac-
I[CV(1MeW)QDWGAHRC]T (1628Da) [22] or a inactive linear
control peptide Ac-IAVVQDWGHHRAT (1532Da) and with
C5aR antagonist AcF-[OPdChaWR] (896Da) [21] or its respec-
tive control peptide Phe-[Orn-Pro-dCha-Ala-D-Arg]. The inhib-
itors and the control peptides were produced in the laboratory of J.
D. Lambris.
Complement- and antibody-binding assays
The cells were mixed with an equal volume of NHS or NHS/
EDTA in sterile polystyrene FACS tubes (BD, Franklin Lakes, NJ).
Non-serum-treated or NHS/EDTA-treated cells were used as
negative/washing controls, respectively. Incubation was carried
out for 20 min at 37uC. Complement activity was stopped by
adding EDTA (final concentration 10 mM). Supernatants were
harvested after pelleting the cells by centrifugation at 900 g for
5 min, and frozen at -70uC. In experiments requiring the presence
of Ca
2+ (detection of MBL, C1q, and annexin-V), cells were
prepared under non-chelating conditions with binding buffer
(10 mM HEPES/NaOH, pH 7.4, with 140 mM NaCl and
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western blotting and FACS were collected after three washes with
PBS/EDTA or binding buffer.
Western blot analysis
SDS-PAGE was performed in a Mini-Protean 3 electrophoresis
apparatus according to the supplier’s instructions (Bio-Rad,
Hercules, CA). Cells were prepared as described above (NHS or
NHS/EDTA in FACS tubes for 20 min at 37uC). To remove
unbound proteins, cell pellets were washed three times with
10 mM PBS/EDTA, resuspended with protease inhibitors
(SigmaFast; Sigma-Aldrich Sweden AB) and incubated with
0.1 M methylamine (pH 9.0) for 1 h at 37uC, to disrupt the
covalent linkage of C3 fragments to the cells. Proteins were
solubilized with lysing buffer (1% SDS, 10 mM Tris-HCL pH 7.4,
and protease inhibitors) and cell debris was pelleted at 13,000 g.
Equal amounts of protein were separated on a 10% SDS-PAGE,
electroblotted onto a PVDF membrane (Perkin-Elmer, Boston,
MA), and probed with a 1:8000 dilution of peroxidase-labeled
rabbit anti-human C3d-HRP and anti-C3c-HRP antibody (Dako,
Glostrup, Denmark). Blots were developed using the enhanced
chemo-luminescence detection kit (Western Lightning; Perkin-
Elmer, Boston, MA). Purified C3b, iC3b, and C3d (1 mg/lane)
were used as positive controls for immunodetection.
Flow cytometry
A. Phenotypic characterization of MSCs. Cell suspensions
were labeled with respective antibodies (Ab), washed and analyzed
on a FACScan flow cytometer (BD Biosciences, San Jose, CA).
Cell acquisition was performed in a forward/sideward scatter
(FSC/SSC) dot plot, cell debris was excluded with FSC, and dead
cells were identified with propidium iodide. Fluorescence signals
from 10,000 – 25.000 events were counted, with detection of
median fluorescence intensity (MFI), and analyzed with Summit
v4.1 software (Dako, Fort Collins, CO). The relative fluorescence
intensity (RFI) was calculated by dividing the MFI of serum-
treated cells by the MFI of non-serum-treated cells. MSCs/ECs
were labeled with the following mouse anti-human mAb’s (all from
BD): isotype controls IgG1-FITC, and IgG2a-PE; negative
controls CD45-FITC, and CD14-PE; positive controls CD90-
FITC, and CD105-PE (Ancell, Bayport, MN); and complement
regulatory proteins CD46-FITC, CD55-FITC, and CD59-PE.
The following rabbit anti-human polyclonal Ab’s were used: C3c-
FITC, C3d-FITC, IgG-FITC, IgM-FITC, and C1q-FITC (all
from Dako, Glostrup, Denmark). Binding of mouse anti-human
iC3b mAb,[25] and mouse anti-human MBL mAb (Hycult
Biotechnology, Uden, NL) was detected with FITC-conjugated
F(ab’)2-fragments of polyclonal rabbit anti-mouse Ab (Dako).
B. Whole-blood analysis. Whole-blood flow cytometric
analysis was performed according to Mollnes et al. [20]. Blood
was distributed equally into surface-heparinized FACS tubes
(Corline Systems, Uppsala, Sweden), and treated with PBS,
EDTA, antagonists, or matched control peptides. The final
concentrations of inhibitors in blood were as follows: EDTA,
10 mM; Compstatin or its control peptide, 60 mM; and C5aRA or
its control peptide, 10 mM. The blood was split equally into two
tubes for each condition and either MSCs or a similar volume of
PBS was added (100 ml/ml). Different doses of MSCs were tested
(0.1-1.0610
6 cells/ml). The samples were incubated at 37uC, and
remaining complement activity was stopped after 40 min by the
addition of EDTA. Sample aliquots of 100 ml blood were collected
after gentle mixing, labeled for 20 min with 5 ml of antibody (anti-
C3c-FITC, or CD11b-FITC and respective isotype controls), and
lysed for 5 min by adding 2 ml FACS lysing solution (BD
Biosciences). The lysed samples were centrifuged at 900 g for
5 min, the supernatants discarded and the cells were washed once
again with 3 ml of PBS; 50,000 events were analyzed. The
remaining blood sample volumes were diluted in an equal volume
of 10 mM PBS/EDTA and centrifuged for 5 min at 2000 g to
yield plasma supernatants for use in ELISA analysis. These
supernatants were stored at -70uC until use.
Mixed lymphocyte reactions
Mixed lymphocyte reactions (MLRs) were performed as
described elsewhere [23]. Responder PBMCs were stimulated
with either PHA-mitogen, or alloantigen-stimulated with a pool of
allogeneic donors (n=5), and irradiated third-party MSCs (P3-5)
were added at a 1:10 ratio to PBMCs. To block complement
function different types of antagonists were added to MLRs: linear
Compstatin, 20 mM; cyclic Compstatin, 20 mM; and cyclic C5aR-
antagonist, 5 mM. MACS-depletion was used to remove the
CD14/CD11b-high fraction from PBMCs (Miltenyi Biotech,
Germany); additionally blocking experiments of complement
receptor 3 (CD11b/CD18) were performed with anti-CD11b
mAb (5 mg/ml; Acris Biotechnology, Germany) or respective
isotype control IgG (5 mg/ml). MSC-mediated suppression of
alloantigen-stimulated PBMC proliferation was assessed at day 5
to 6 with [
3H]thymidine incorporation (18 h) as counts per minute
(cpm).
ELISA analysis
C3a and sC5b-9 generation in plasma supernatants was
measured by ELISA according to the method of Nilsson Ekdahl
et al. [26]. Values are expressed in ng/ml and AU/ml,
respectively, if not otherwise indicated.
Statistical analysis
Statistical analyses were performed using Student’s t-test or
ANOVA. If the data did not fit normal distribution the Mann-
Whitney test or the Wilcoxon matched pairs test was used (two-
tailed confidence intervals, 95%; P,0.05 was considered statisti-
cally significant; Prism 5.0; Graphpad Software).
Results
MSCs and ECs display differential complement activating
and regulatory properties
Flow cytometry was used to characterize the binding of
complement factor C3 fragments to MSCs and HUVECs after
the cells were incubated with complement-active normal human
serum (NHS). MSCs showed a signal shift for anti-C3c detection
relative to non-serum-treated cells or HUVECs treated in a similar
fashion (Fig. 1A). Binding of C3 fragments was only observed after
incubation with complement-active NHS, but not after treatment
with EDTA-inactivated NHS (NHS/EDTA), demonstrating that
C3 fragments only bound when complement was active.
Significantly higher levels of C3 fragments were bound to the
cell surface of MSCs, as compared to HUVECs (P,0.001,
Fig. 1B), which was accompanied by C3a formation in the
supernatants (P,0.05). Activation and subsequent binding of C3
to the surface of MSCs could be prevented by pre-treatment of
NHS with Compstatin in a dose-dependent manner (Fig. 1C).
NHS-treatment did not result in increased propidium iodide-
incorporation, Annexin-V-binding, or lysis of MSCs, as compared
to NHS/EDTA treated cells (data not shown).
In order to study the intrinsic complement regulatory capacity
of the two cell types, we analyzed the expression of complement
regulatory proteins CD46, CD55, and CD59. Trypsin detached
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to medium passage MSCs (P4-6) which had been harvested in a
similar fashion expressed only CD59, but showed a relative lack
for expression of CD46 and CD55 (both P,0.01, Fig. 2A), which
suggests a substantial lack in complement regulatory capacity for
culture expanded MSCs. We also studied the differential cell
surface binding of complement activating factors (Fig. 2B). Both
cell types bound small amounts of immunoglobulins, but no
significant differences in binding of IgG, IgM, C1q, and MBL
were found. The strongest positivity was found for the most part
on necrotic cells, as identified by propidium iodide incorporation
(data not shown).
In order to clarify the specific profile of C3 fragments bound to
the MSC-surface we performed flow cytometric analysis with
antibodies which have reactivity against the C3c-, iC3b- and C3d-
epitopes within the C3 molecule. We found that MSCs bound
higher amounts of all three fragments on their cell surface (P,0.05
and P,0.001, Fig. 2B), which did not occur with EDTA-
inactivated NHS. The presence of iC3b on MSCs was
furthermore suggested by western blot experiments using poly-
clonal anti-C3c and C3d antibodies (Fig. 2C, lane 1). Bands with
strong reactivity for C3 epitopes were detected on NHS-treated,
but not on NHS/EDTA-treated MSCs. These bands correspond-
ed to the 63- and 40-kDa fragments of the beta- and alpha- chain
of control iC3b, respectively. Higher molecular weight bands
(.110 kDa) larger than the native C3 alpha-chain were also
found. No iC3b was found on HUVECs. Most interestingly,
freshly thawed MSCs (as prepared for clinical use) displayed much
higher degrees of complement fragment binding than did freshly
trypsinized cells (data not shown), which indicates that minor
damage to the cell-surface integrity/polarity as a result of the
freeze/thaw procedure might have affected their complement
triggering/regulating properties.
Complement-mediated modulation of MSC-induced
effector cell priming in human blood
Since clinical MSCs are applied via systemic infusion to our
HSCT patients, we simulated the exposure of MSCs to lepirudin-
anticoagulated ABO-compatible human blood in vitro. Lepirudin
Figure 1. MSCs and ECs activate complement to different
degrees. Freshly trypsinized MSCs (black) and HUVECs (white) were
exposed to complement active normal human serum (NHS) in order to
study the cell surface binding of complement activation products with
flow cytometry. (A) Histogram overlays for binding of anti-C3c antibody
to non-serum-treated cells (empty, dotted), NHS- (black), or NHS/EDTA-
treated cells (shaded) is shown after a 20 min incubation with the
respective sera at 37uC. Complement-inactivated NHS (NHS/EDTA)
served as negative control. (B) Box plots (whiskers min/max) for anti-
C3c binding (RFI, left panel, n=11) and C3a generation in supernatants
(ng/ml, right panel, n=8) after incubation of cells with NHS, the relative
fluorescence intensity (RFI) was calculated compared to non-serum-
treated cells. The data are expressed as means6SEM, *P,0.05, and
***P,0.001. (C) Inhibition of C3 fragment binding after pre-treatment
of NHS with different doses (5-120 mM) of specific C3-inhibitor
Compstatin (n=5).
doi:10.1371/journal.pone.0021703.g001
Figure 2. MSCs and ECs differ in their complement regulatory
activity. (A) Expression of complement regulatory proteins MCP
(CD46), DAF (CD55), and CD59 on MSCs and HUVECs (n=11 each) was
quantified with flow cytometry (MFI, median fluorescence intensity). (B)
Cell surface binding of immunoglobulins (IgG and IgM) and specific C3
fragments (iC3b, C3d, C3c) was analyzed after cell treatment with NHS
or NHS/EDTA and labeling with specific antibodies directed against the
following epitopes: IgG (n=8), or IgM (n=8); iC3b (n=5), C3d (n=9),
C3c (n=15). (C) Representative western blot for detection of C3c, iC3b
and C3d epitopes bound to NHS or NHS/EDTA treated cells. Purified
C3b, iC3b and C3d served as positive controls. The data in figure A and
B are means6SEM, with: *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0021703.g002
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agreement with our prior findings in NHS, exposure of lepirudin-
blood to MSCs revealed a significant increase in generation of
complement activation product C3a (P,0.001, Fig. 3A) and
soluble C5b-9 complex (P,0.01, Fig. 3B), which is indicative for
formation of C5a. Flow cytometric analysis of MSCs and different
blood effector cells (Fig. 3C), confirmed the activation and binding
of C3 fragments to MSCs in blood (shown in red), which was
accompanied by triggering of CD11b on neutrophil granulocytes
(shown in green, P,0.001, Fig. 3D) and monocytes (data not
shown). We furthermore analyzed the general activation of effector
cells by detecting morphological changes with flow cytometry
(Table S1), which revealed a significant reduction in the number of
resting monocytes and lymphocytes (P,0.001 and P,0.01), and
an increase in activated lymphocytes and monocytes (both
P,0.01) in response to MSCs. But no significant changes in
percentage of gated MSCs was found when active blood was
compared to EDTA-inactivated control blood (8.164.4 vs.
7.364.6), which indicates that no immediate complement- or
effector cell-mediated lysis of MSCs had taken place (Fig. 3E). To
verify if the activation of effector cells after contact with MSCs is
mediated via complement signalling we blocked complement
function by pre-treatment of blood with Compstatin, which lead to
strongly reduced formation of both C3a and sC5b-9 (P,0.05,
Fig. 4A and 4B). Compstatin furthermore abrogated triggering of
CD11b on effector cells (P,0.05, Fig. 4C, left panel), which could
also be blocked with a specific C5a receptor antagonist (P,0.05,
Fig. 4C, right panel). But neither formation of C3a, sC5b-9, or
triggering of CD11b was affected by the corresponding control
peptides.
The complement-activating properties of MSCs affect
their immunomodulatory profile
Many clinical applications of MSCs are based on their
immunomodulatory properties and tests to determine the potency
of MSCs to elicit desired clinical responses would be anticipated.
We therefore screened the suppressive effect of more than 60
individual MSCs in mixed lymphocyte reactions (MLRs), and
found that MSCs show a broad donor specific variation in their
suppressive properties, with an average inhibition of about 60%
(Fig. 5A). Whilst some MSCs were highly suppressive in a
consistent fashion (e.g. Kd086, K03, K22, K29, L82, L113), others
showed strong variation (e.g. K01, L10, L43, L61, L118), some
suppressed poorly (e.g. Kd029, KD050, K14, K15, L10), whereas
Figure 3. Blood exposure of MSCs activates complement and
effector cells. Lepirudin-anticoagulated blood was incubated with
MSCs (black), and blood treated with either PBS (white) or 10mM EDTA
(shaded) served as active or inactive control, respectively. (A) Plasma
levels of C3a (ng/ml, n=13), and (B) Plasma level of soluble C5b-9
complex (AU/ml, n=13) were detected with ELISA. (C) Flow cytometric
analysis of PBMCs and MSCs after labeling of individual blood aliquots
with specific antibodies and subsequent erythrocyte lysis; the cells were
first gated according their scatter profile (top panel, scatter plot) and
representative histograms for triggering of CD11b-expression on PMNs
(green) or binding of C3-fragments to MSCs (red) are shown compared
to EDTA-inactivated negative control blood (grey histograms). (D) Up-
regulation of CD11b on PMNs in blood (MFI, n=19). The median
fluorescence intensity (MFI) of the cell-surface marker CD11b was
assessed with flow cytometry. (E) Percentage of recovered MSCs after a
40 min exposure to active or EDTA-inactivated blood (n=17). The data
in figure A-E are means6SEM; with: ns=not significant; **P,0.01, and
***P,0.001.
doi:10.1371/journal.pone.0021703.g003
Figure 4. Effector cells activation in blood is mediated by
complement activation products. Lepirudin-anticoagulated blood
was pre-treated with either complement antagonist compstatin or a
specific C5a receptor antagonist (C5aRA), and their respective control
peptides, and then incubated for 40 min with either MSCs (black) or
PBS (white) as negative control (n=6). (A) Relative generation [%] of
C3a and (B) sC5b-9 in blood after incubation w/wo MSCs in presence of
cyclic compstatin or its linear control peptide (both 60 mM). The results
are presented relative to active non-MSC-treated blood, which was set
to be 100%. (C) Upregulation of CD11b on PMNs in blood treated w/wo
MSCs in presence of cyclic compstatin or control peptide (60 mM), and
C5aR-antagonist (C5aRA) or control peptide (10 mM). The data in figure
in A-C are means6SEM, with *P,0.05.
doi:10.1371/journal.pone.0021703.g004
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and their immunomodulatory properties. (A) Suppression of PBMC-proliferation by MSCs was tested in MLRs. Retrospective analysis is shown
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L61). In an attempt to identify the most beneficial phenotype we
correlated the average suppressive activity of MSCs in MLRs with
their clinical response in patients.
Forty-two patients received 64 MSC infusions as experimental
treatment of life-threatening complications to HSCT, with
indication for ameliorating aGvHD and tissue damage. Patient
characteristics are shown in table 1. No adverse events during or
after MSC infusion were observed. Patients responded to 66% of
infusions with 14 partial and 28 complete responses. We
performed retrospective analysis of the clinical response to each
individual MSC-infusion and found a weak inverse correlation
with their average suppressive activity in MLRs (not shown).
MSCs given to complete responders showed an average
suppressive activity of ,50% in MLRs, whereas non-responders
had a significantly higher suppressive effect (P,0.0012, Figure 5B),
which suggests that a strong suppressive activity of MSCs on
PBMC-proliferation in vitro does not necessarily indicate a high
therapeutical value for modulation of immune responses in vivo.
To investigate weather the complement triggering properties of
MSCs affect their immunomodulatory profile in vitro we repeatedly
tested MSCs from 10 different cell donors; We quantified their
average C3-fragment binding capacity and set a threshold (at
RFI=10), to distinguish between weakly or strongly complement
activating cells (Fig. 5C). Highly C3 activating MSCs (C3-high,
RFIC3c.10) showed to be far superior to C3-low cells
(RFIC3c,10) in suppressing PBMC proliferation in vitro
(P,0.001, Fig. 5D), and furthermore showed to be much more
efficient in triggering of CD11b
+-effector cells in whole blood
(P,0.001, Fig. 5E). We consequently depleted the CD14
+-cells
from PBMCs, which lead to an efficient removal of CD14/
CD11b-high myeloid effector cells from MLRs (P,0.05, Fig. 5F).
The suppressive activity of MSCs was abrogated in monocyte
depleted alloantigen-stimulated MLRs (P,0.01, Fig. 5G), and also
significantly reduced after inhibition of complement at its central
activation step C3 with Compstatin (P,0.05, Fig. 5G), but was not
affected by its linear control peptide. Blocking of individual
receptors downstream of C3, such as the C5a receptor with C5aR-
antagonist, and complement receptor 3 (CD11b/CD18) with a
CD11b blocking antibody was not sufficient to impair the
suppressive activity of MSCs in MLRs (data not shown).
Discussion
In recent years, the interaction of MSCs with the adoptive
immune system has been extensively studied [27]. However, their
relationship to the innate immune system has scarcely been
addressed so far, focusing primarily on innate effector cells and
toll like receptors [9,27]. In the present study, we have investigated
the interactions between culture-expanded MSCs and the comple-
ment system, which plays an important role in host defense, and in
modifying immune responses in vivo [12,13]. Here, we report for the
first time that exposure of MSCs to complement-active human
serum and blood leads to deposition of complement activation
products on the cell surface of MSCs and generation of soluble
anaphylatoxins. This process led to a complement-mediated
triggering of effector cell activation, via the engagement of
complement receptor type 3 (CD11b/CD18). The complement-
activating properties of these cells were correlated with their
immunomodulatory capacity to suppress PBMC-proliferation in
vitro. The suppressive effect of MSCs could be blocked by inhibiting
complement function or by removal of myeloid effector cells from
MLRs. Thus, it appears that complement activation plays an
important role in mediating the activation and interaction of MSCs
with different types of complement receptor-bearing effector cells in
human blood, potentially triggering their own intrinsic immuno-
suppressive functions and that of other effector cells, to generate a
complex immunosuppressive environment (Figure S1).
It is generally believed that bone marrow derived MSCs migrate
throughout the vascular system and home to specific target sites in
vivo, but whether trafficking of MSCs occurs via the blood stream
in healthy adults remains controversial [28]. We speculated that
MSCs have a certain degree of intrinsic blood compatibility, such
as attributed to endothelial cells (ECs), and studied how they
interact with the complement system upon exposure to human
serum. In our first set of experiments, we saw an enhanced cell
surface C3-fragment deposition (iC3b and C3dg) and fluid phase
generation of C3a after exposure of MSCs to human serum.
Interestingly, Schraufstatter et al. recently demonstrated that
complement anaphylatoxins C3a and C5a bind to their concom-
itant receptors on MSCs, which are then quickly translocated to
the cell nucleus, where they trigger cell activation and chemotactic
responses of these cells [15]. Furthermore, it was shown that
complement modulates the inflammatory response of mesenchy-
mal and more mature osteoblastic cells [29]. The activation of
complement on the surface of culture expanded MSCs and the
generation of anaphylatoxins in proximity to respective receptors
on these cells may therefore provide a fast auto-activation loop,
which could potentially trigger the immunosuppressive function of
MSCs directly after systemic infusion. The requirement of this
initial licensing step for MSC-function has already been well
described for a number of pro-inflammatory cytokines such as
interferon gamma [10]. Complement activation may therefore
provide yet another powerful signal to activate the intrinsic defense
mechanisms of MSCs after systemic infusion.
Cells in contact with blood are normally equipped to down-
regulate complement activation via expression of complement
regulatory proteins such as MCP, DAF, and CD59, which are
typically found on ECs [30]. Culture-expanded MSCs lacked
MCP and DAF, but were protected from complement-mediated
lysis by the expression of CD59. We investigated potential
complement-triggering factors and the specific profile of C3
fragments deposited onto the surface of MSCs, by using methods
(2003 – 2011), with an average of n=5 MLR-experiments for each individual MSC-donor versus 3-5 random PBMC donors, the dotted line indicates
overall average suppression (,60%); (B) Average suppression of MSCs in MLRs and resulting clinical response to MSCs therapy (PD, progressive
disease; SD, stable disease; PR, partial response; and CR, complete response); (C) MSC-donor specific differences in cell surface binding of C3-
fragments after incubation with NHS as detected by binding of anti-C3c with flow cytometry (RFI, n.5 each donor), dotted line indicates threshold
for C3-low (average RFIC3c,10) and C3-high cells (RFIC3c.10); (D) Statistical comparison for suppressive potency of MSCs in MLRs, when grouped into
C3-low and C3-high cells (n=17 each); (E) Flow cytometric analysis on CD11b-triggering activity of MSCs in human blood (MFI CD11b on PMNs),
when compared for C3-low (n=6) and C3-high cells (n=14), relative to PBS- or EDTA-treated control blood. (F) MACS depletion of CD14+ cells from
PBMCs efficiently removes of CD11b-high monocytes but not CD11b-low NK cells from MLRs (n=5). (G) Suppression of PBMC-proliferation by MSCs
in MLRs (n.3 experiments) with various combinations of MSCs (n=5 donors), responder PBMCs (n=2), and 2 different pools of allogeneic stimulator
PBMCs (n=5 donors), which were tested in the presence of different inhibitory treatments: untreated MLRs (n=13, white), control peptide (linear
Compstatin 20 mM, n=13, light grey), cyclic Compstatin (20 mM, n=13, dark grey), or with monocyte depletion (CD14/CD11b high cells, n=9, black).
The values in A-E are means6SEM, with *P,0.05, **P,0.01, and ***P,0.001.
doi:10.1371/journal.pone.0021703.g005
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[31]. Flow cytometry and western blot analysis showed cell-surface
deposition of iC3b and C3dg on MSCs. Two typical mediators of
complement activation are the recognition molecules C1q
(classical pathway), which preferentially binds to antibodies, and
MBL (lectin pathway), recognizing non-self carbohydrate ligands.
Both cell types bound similar, but very low amounts of
immunoglobulins. Scarce amounts of C1q and MBL were found
to be primarily associated with non-vital cells, in agreement with
the literature; typically, only late apoptotic or necrotic cells are
recognized by these pattern recognition molecules [32].
To further investigate the biological potential of our findings, we
used lepirudin anti-coagulated blood in order to perform more
detailed studies on the interactions between MSCs and different
types of blood effector cells without impairing complement function
[20]. We found an enhanced generation of complement anaphyl-
atoxins C3a and C5a,but no complement-mediated lysis of MSCsin
blood. We also found activation of different types of blood effector
cells, as indicated by triggering of CD11b-expression on PMNs and
monocytes in response to MSCs. Compstatin was effective in
blocking complement activation, which led to a reduction in C3
fragment deposition and anaphylatoxin generation. Both Comp-
statin and the C5aR antagonist successfully prevented the upregula-
tion of CD11b on PMNs. Most importantly, both the degree of
complement triggering elicited by MSCs and the resulting intensity
of CD11b-mediated effector cell priming were correlated with the
capacity of these cells to suppress the proliferation of PBMCs in vitro.
To understand the role of complement activation in this process
we performed different blocking and cell depletion experiments
and found that inhibition of complement at its central activation
step C3 with Compstatin could diminish the suppressive effect or
MSCs in vitro. This could not be achieved by inhibiting single
downstream events of C3-activation, e.g. by blocking the C5a
receptor or by blocking complement receptor 3. However,
removal of CD14/CD11b-high myeloid effector cells (monocytes),
strongly impaired the immunosuppressive function of MSCs in
vitro, which is in agreement with earlier observations by Groh et al.
who found that MSCs engage monocytes to elicit their
immunosuppressive effects [33]. To clarify if a highly suppressive
MSC-phenotype is actually associated with a beneficial clinical
response in vivo we repeatedly tested the suppressive effect of
clinical MSCs in alloantigen- and PHA-stimulated MLRs. We
thereby obtained their average suppressive activity, which was
then correlated with the degree of their individual clinical response
obtained in treatment of acute GvHD and hemorrhagic cystitis. It
appeared that MSCs with a medium suppressive activity are
therapeutically more beneficial then highly MLR-suppressing
MSCs, which might indicate that the strongly complement
depositing phenotype is less favourable for therapeutical use.
A growing body of evidence suggests that the clinical infusion of
MSCs can transform a pro-inflammatory environment into a
milieu that favors healing and the suppression of allogeneic
responses. This effect might be mediated by soluble factors and the
generation of suppressive myeloid and lymphoid cell subsets.
Many investigators have shown that MSCs inhibit the function of
effector cells and may even polarize their phenotype to an
immunosuppressive one, which possibly augments their own
intrinsic immunosuppressive function [27]. Recent studies have
pointed to the generation of suppressive myeloid cells after close
interaction with MSCs, but the nature of this interaction was
found to be elusive [8,9]. This report shows that complement
activation serves as a mediator between MSCs and complement
receptor bearing immune cells, such as CD11b+-myloid and NK
cells, and that complement activation augments the immunomod-
ulatory activity of MSCs in vitro. Our findings also demonstrate
that strongly complement activating MSCs might not essentially
be more valuable for therapeutical use, since average suppressors
appeared to yield the most beneficial therapeutical effect in vivo.
Our results may contribute to the understanding and interpreta-
tion of complement mediated interactions of MSC with other
immune cells in vitro and in vivo.
Supporting Information
Figure S1 The complement-activating properties of
mesenchymal stem cells (MSCs). Triggering of complement
activation on the surface of MSCs leads to C3 convertase-
Table 1. Patients treated with MSCs.
Patients
Sex (M/F) 30/12











Indication for MSC treatment:
Graft-versus-host disease 28
Hemorrhagic cystitis 14
Clinical response to treatment: 28/42 (67%)
Complete response 20/42 (48%)
Partial response 08/42 (19%)
Stable disease 03/42 (07%)
Progressive disease 11/42 (26%)
MSC donors
Sex (M/F) 16/17
Age median (range) 37 (1-66)
Cell dose median (range) (610
6/kg) 1.6 (0.6-3.0)
Cell passage median (range) 3.0 (1.0-4.0)
Number of MSC infusions: 64
HLA-match with recipient:
3
rd party unrelated donor 50
Haploidentical related donor 11
HLA-identical sibling 3
Clinical response to treatment: 42/64 (66%)
Complete response 28/64 (44%)
Partial response 14/64 (22%)
Stable disease 08/64 (13%)
Progressive disease 14/64 (22%)
Abbreviations: MAC, myeloablative conditioning; RIC, reduced intensity
conditioning; CsA, cyclosporine; MTX, methotrexate; and HLA, human leukocyte
antigen.
doi:10.1371/journal.pone.0021703.t001
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fragments C3a and C3b. The covalently bound C3b can be
degraded to iC3b by factor I. C3b and its degradation products
mediate phagocytosis and immune responses via complement
receptors, such as CR3 (CD11b/CD18), on host cells. Accumu-
lation of C3b leads to assembly of C5 convertases that activate C5
to C5a and C5b, which may eventually lead to formation of the
lytic membrane attack complex (MAC). However, cell lysis can be
prevented by the complement regulatory function of membrane
protein CD59. Anaphylatoxins C3a and C5a induce cell activation
and chemotactic responses by binding to their receptors C3aR and
C5aR on host cells and MSCs, which may promote interaction
with various types of CR-bearing cells. Activated MSCs may
reprogram host cells to synergistically produce an anti-inflamma-
tory microenvironment composed of many different factors
(iNOS/NO, IDO/kynurenine, HO-1/biliverdin and CO, PGE2,
Galectin-1, TSG-6, sHLA-G5, HGF, IL6, IL10, TGFb, IL1Rag),
and may suppress allogeneic immune responses in vivo.
(TIF)
Table S1 MSC-induced effector cell activation in whole
blood. * Percentage (means6SD, n=14) of resting or activated
effector cells is shown for blood treated w/wo MSCs. *P,0.05,
**P,0.01, and ***P,0.001 relative to non-MSC-treated blood.
(DOCX)
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